Eli Lilly shares are trading higher following a series of positive developments that reinforce the company's leadership in the obesity and diabetes market. Building on momentum from the previous evening, the company announced the groundbreaking of a 3.5 billion dollar manufacturing site in Pennsylvania dedicated to next-generation injectable obesity medicines. This expansion follows news from earlier in the week regarding the approval of its weight-loss pill orforglipron in China and a new partnership with Hims and Hers to increase patient access to Zepbound and Foundayo. These operational milestones, combined with a broader investor rotation into defensive healthcare stocks, have supported the stock's performance during the session.